We successfully prepared a new Cu(ii)-BODIPY PS complex (CA9-BPS-Cu(ii)) containing a CA9-targeting ligand, acetazolamide, and demonstrated its efficacy in promoting a synergistic CDT/PDT effect with CSC targeting to enhance cancer therapy in vitro and in vivo. This evidence concerns the gene CA9 and cancer.